| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | GRA6 |
| Uniprot No | Q27003 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-150aa |
| 氨基酸序列 | NSLGGVAVAADSGGVKQTPSETGSSGGQQEAVGTTEDYVNSSAMGGGQGDSLAEDDTTSEAAEGDVDPFPVLANEGKSEARGPSLEERIEEQGTRRRYSSVQEPQAKVPSKRTQKR |
| 预测分子量 | 38.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GRA6重组蛋白的3篇参考文献示例(文献为虚拟示例，仅作格式参考)：
---
1. **文献名称**：*Evaluation of recombinant GRA6 antigen for serodiagnosis of Toxoplasma gondii infection*
**作者**：Li, X. et al.
**摘要**：研究评估了重组GRA6蛋白在弓形虫血清学诊断中的应用，通过ELISA验证其特异性，显示与传统方法相比具有更高的敏感性，提示其作为诊断标志物的潜力。
2. **文献名称**：*Immunogenicity of recombinant GRA6 protein in a murine model of toxoplasmosis*
**作者**：Zhang, Y. et al.
**摘要**：在小鼠模型中，重组GRA6蛋白可诱导强烈的Th1型免疫反应，显著降低组织内弓形虫包囊数量，表明其在疫苗开发中的潜在价值。
3. **文献名称**：*Structural and functional analysis of Toxoplasma gondii GRA6 recombinant protein*
**作者**：Wang, Q. et al.
**摘要**：通过重组表达和晶体结构解析，揭示了GRA6蛋白与宿主细胞相互作用的分子机制，为靶向药物设计提供了理论基础。
---
**注**：以上文献为示例，实际研究中建议通过PubMed、Web of Science等平台检索真实文献(关键词：GRA6 recombinant protein, Toxoplasma gondii diagnosis/vaccine)。
**Background of GRA6 Recombinant Protein**
*Toxoplasma gondii*, an obligate intracellular protozoan parasite, infects humans and animals worldwide, causing toxoplasmosis. Among its virulence factors, dense granule proteins (GRAs) play critical roles in host cell invasion, parasitophorous vacuole formation, and immune modulation. GRA6. a 32-kDa protein secreted by the parasite’s dense granules, is implicated in intracellular survival and host-pathogen interactions.
GRA6 recombinant protein is produced via genetic engineering, typically by expressing the *GRA6* gene in bacterial or eukaryotic systems. This allows large-scale purification for research and diagnostic applications. Studies highlight GRA6’s role in stimulating host immune responses. It contains immunodominant epitopes recognized by both CD4+ and CD8+ T cells, making it a potential target for vaccine development. In murine models, GRA6-based vaccines have shown partial protection against *T. gondii* infection by inducing Th1-type immune responses.
Structurally, GRA6 possesses a C-terminal amphipathic alpha-helical domain, enabling membrane interactions and contributing to the parasitophorous vacuole’s architecture. Its ability to bind calcium suggests a role in modulating intracellular signaling or nutrient acquisition. Additionally, GRA6 exhibits genetic polymorphism across *T. gondii* strains, influencing antigenic variability and diagnostic assay design.
In diagnostics, recombinant GRA6 serves as an antigen in serological tests to detect anti-*Toxoplasma* antibodies, aiding in differentiating acute and chronic infections. However, cross-reactivity with other GRAs or related pathogens remains a challenge.
Overall, GRA6 recombinant protein is a valuable tool for understanding *T. gondii* pathogenesis, advancing vaccine strategies, and improving diagnostic precision, though further research is needed to optimize its applications.
×
